Eam Investors, LLC Dia Medica Therapeutics Inc. Transaction History

Eam Investors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$2.56 - $4.4 $148,241 - $254,790	-57,907 Reduced 21.41%	212,512 $548,000
Q2 2023 Aug 11, 2023	BUY	$1.53 - $4.4 $413,741 - $1.19 Million	270,419 New	270,419 $1.17 Million
Q2 2021 Aug 13, 2021	SELL	$4.45 - $9.91 $481,632 - $1.07 Million	-108,232 Closed	0 $0
Q1 2021 May 11, 2021	SELL	$7.76 - $10.43 $13,603 - $18,283	-1,753 Reduced 1.59%	108,232 $990,000
Q4 2020 Feb 11, 2021	BUY	$4.13 - $10.14 $454,238 - $1.12 Million	109,985 New	109,985 $1.12 Million

4.22M

8.2K

200

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $128M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.